BIOA Stock Analysis: BioAge Labs | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.082m USD | 12M Return: 370.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.8M
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 1.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioAge Labs (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases. The company was founded in 2015, is headquartered in Emeryville, California, and completed its IPO in September 2024, trading as a small-cap within the Health Care / Pharmaceuticals segment.
The companys approach is built on a platform that analyzes proprietary human datasets to identify molecular drivers of aging, which it then translates into drug targets. Its lead candidate, BGE-102, is an oral, brain-penetrant small-molecule NLRP3 inhibitor currently in Phase 1 development for atherosclerotic cardiovascular disease, diabetic macular edema, and geographic atrophy. BioAge is also developing APJ agonists for obesity, with both oral and parenteral (injectable) formulations in its pipeline.
BioAge has a collaboration agreement with Novartis Pharma AG focused on identifying and validating therapeutic targets linked to aging-related disease mechanisms. As a clinical-stage company with no approved products, BioAges value proposition is centered on its discovery platform, early-stage pipeline, and strategic partnerships that help support research and development funding.
- BGE-102 NLRP3 inhibitor Phase 1 data readout in cardiovascular and ophthalmology indications
- APJ agonist obesity pipeline competes in crowded GLP-1 dominated market
- Novartis collaboration validates aging targets and unlocks potential milestone payments
| Net Income: -89.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA -6.58 > 1.0 |
| NWC/Revenue: 3.65k% < 20% (prev 20.7k%; Δ -17.1k% < -1%) |
| CFO/TA -0.22 > 3% & CFO -88.3m > Net Income -89.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.5m) vs 12m ago 18.49% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.78% > 50% (prev 0.42%; Δ 2.36% > 0%) |
| Interest Coverage Ratio: -186.0 > 6 (EBIT TTM -89.4m / Interest Expense TTM 481k) |
| A: 0.95 (Total Current Assets 391.9m - Total Current Liabilities 15.8m) / Total Assets 397.7m |
| B: -0.89 (Retained Earnings -355.7m / Total Assets 397.7m) |
| C: -0.24 (EBIT TTM -89.4m / Avg Total Assets 370.7m) |
| D: 20.46 (Book Value of Equity 379.1m / Total Liabilities 18.5m) |
| Altman-Z'' = 23.15 = AAA |
| DSRI: 0.28 (Receivables 709k/361k, Revenue 10.3m/1.45m) |
| GMI: 1.02 (GM 100.0% / 97.94%) |
| AQI: 0.12 (AQ_t 0.01 / AQ_t-1 0.04) |
| SGI: 7.11 (Revenue 10.3m / 1.45m) |
| TATA: -0.00 (NI -89.9m - CFO -88.3m) / TA 397.7m) |
| Beneish M = 0.25 (Cap -4..+1) = D |
As of July 14, 2026, the stock is trading at USD 21.79 with a total of 547,538 shares traded. Over the past week, the price has changed by -12.30%, over one month by +9.80%, over three months by +34.56% and over the past year by +370.52%.
Current recommended Stop Loss: 17.40 (which is 20.1% or 2.9 ATR below the current price).
BioAge Labs has received a consensus analysts rating of 2.50. Therefore, it is recommended to sell BIOA.
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 49.5 | 127.2% |
P/S = 107.2536
P/B = 2.7713
Revenue TTM = 10.3m USD
EBIT TTM = -89.4m USD
EBITDA TTM = -89.2m USD
Long Term Debt = 2.23m USD (estimated: total debt 4.03m - short term 1.80m)
Short Term Debt = 1.80m USD (from shortTermDebt, last quarter)
Debt = 6.91m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.88m
Net Debt = -376.3m USD (calculated: Debt 6.91m - CCE 383.2m)
Enterprise Value = 705.7m USD (1.08b + Debt 6.91m - CCE 383.2m)
Interest Coverage Ratio = -186.0 (Ebit TTM -89.4m / Interest Expense TTM 481k)
EV/FCF = -7.96x (Enterprise Value 705.7m / FCF TTM -88.6m)
FCF Yield = -12.56% (FCF TTM -88.6m / Enterprise Value 705.7m)
FCF Margin = -859.1% (FCF TTM -88.6m / Revenue TTM 10.3m)
Net Margin = -871.8% (Net Income TTM -89.9m / Revenue TTM 10.3m)
Gross Margin = unknown ((Revenue TTM 10.3m - Cost of Revenue TTM 213k) / Revenue TTM)
Tobins Q-Ratio = 1.77 (Enterprise Value 705.7m / Total Assets 397.7m)
Interest Expense / Debt = 6.96% (Interest Expense 481k / Debt 6.91m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -70.7m (EBIT -89.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 24.76 (Total Current Assets 391.9m / Total Current Liabilities 15.8m)
Debt / Equity = 0.02 (Debt 6.91m / totalStockholderEquity, last quarter 379.1m)
Debt / EBITDA = 4.22 (negative EBITDA) (Net Debt -376.3m / EBITDA -89.2m)
Debt / FCF = 4.25 (negative FCF - burning cash) (Net Debt -376.3m / FCF TTM -88.6m)
Total Stockholder Equity = 305.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.26% (Net Income -89.9m / Total Assets 397.7m)
RoE = -29.40% (Net Income TTM -89.9m / Total Stockholder Equity 305.9m)
RoCE = -29.03% (EBIT -89.4m / Capital Employed (Equity 305.9m + L.T.Debt 2.23m))
RoIC = -18.44% (negative operating profit) (NOPAT -70.7m / Invested Capital 383.1m)
WACC = 11.93% (E(1.08b)/V(1.09b) * Re(11.97%) + D(6.91m)/V(1.09b) * Rd(6.96%) * (1-Tc(0.21)))
Discount Rate = 11.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.04 | Cagr: 286.9%
[DCF] Fair Price = unknown (Cash Flow -88.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.09 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.63 | Chg30d=+0.00% | Revisions=+29% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.66 | Chg30d=+0.00% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=-2.49 | Chg30d=+0.00% | Revisions=+29% | GrowthEPS=-11.2% | GrowthRev=+503.6%
EPS next Year (2027-12-31): EPS=-2.06 | Chg30d=+0.00% | Revisions=+29% | GrowthEPS=+17.3% | GrowthRev=-34.8%
[Analyst] Revisions Ratio: +32% (up=11, down=5)